# MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
Canonical URL: https://biopharmsignal.com/news/MGNX/macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyzr-royalty-purchase-agreement
Ticker: MGNX
Company: MacroGenics
Source: MacroGenics
Published: 2026-05-04 11:30 EST
Original Source URL: https://ir.macrogenics.com
## Summary

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc.

## Article Body
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
## Recent Company News
- 2026-05-14 20:01 EST — [MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2026-virtual-targeted-oncology-forum) — Source: MacroGenics
- 2026-05-13 20:01 EST — [MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation](https://biopharmsignal.com/news/MGNX/macrogenics-reports-first-quarter-2026-financial-results-and-highlights-business-transformation) — Source: MacroGenics
- 2026-05-11 21:20 EST — [MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals](https://biopharmsignal.com/news/MGNX/macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals) — Source: MacroGenics
- 2026-05-04 11:30 EST — [MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement](https://biopharmsignal.com/news/MGNX/macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyzr-royalty-purchase-agreement) — Source: MacroGenics
- 2026-04-08 20:30 EST — [FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study](https://biopharmsignal.com/news/MGNX/fda-removes-partial-clinical-hold-on-macrogenics-linnet-study) — Source: MacroGenics
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)